U.S. Castle Creek Pharma secures $71.8 million in funding round

10/20/2018 11:01:00 AM (GMT)

Castle Creek Pharma, a U.S.-based biopharmaceutical company, received $71.8 million in funding round.

Backers included U..S-based investment management firm Fidelity Management & Research Company and Valor Equity Partners.

Castle Creek intends to use the funds to continue to develop CCP-020 as an important treatment for epidermolysis bullosa simplex (EBS).

With this new capital, the company has invested a total of $122.5 million into the development of innovative therapies for patients with rare dermatologic conditions including EBS.

Castle Creek Pharma

All success stories are prepared by Investsize editors which is selecting elite and remarkable information from press releases and anonymous news sources.There is no charge applied for any success stories which is published . Those published success stories are not investment advices and doesnt offer recommendations Alternate Text